top of page

Solving Complex Diseases at the Genomics Level

Decoding the Language of Life

Elevating life sciences with AI-integrated functional genomics to advance cancer treatment, neurodegenerative disease management, and longevity.

Thanks for submitting!

cognit.ai-ff-BG-01.png

Cognit's Innovation

Cognit is crafting a cross-cell, cross-species Frontier AI model in Generative Biology that simulates biological cells and enables high-resolution functional genomics through closed-loop, in-silico, gene and cell engineering, redefining the paradigms in genomics research. 

Screenshot 2023-10-18 at 2.59.42 PM.png
Screenshot 2024-06-10 at 2.54.03 PM.png
Screenshot 2024-06-10 at 2.57.12 PM.png
Screenshot 2024-09-25 at 3.22.13 PM.png

Cognit's Focus

Screenshot 2024-01-18 at 4.03.36 PM.png
Screenshot 2024-01-10 at 5.26.28 PM.png
Screenshot 2023-10-18 at 3.33.56 PM.png

Industries Empowered by Cognit to Build on Our AI Platform

Screenshot 2023-10-18 at 3.24.18 PM.png
Screenshot 2023-10-18 at 3.04.47 PM.png
Screenshot 2023-10-18 at 3.24.35 PM.png
Screenshot 2023-10-18 at 3.04.36 PM.png

The current state of drug discovery is inefficient and expensive. It takes an average of 12 years and $2.6 billion to bring a new drug to market.

This is due in part to the fact that drug discovery is largely a trial-and-error process. Researchers must first identify a target gene, then develop a drug that can modulate that gene's expression. This process is often time-consuming and expensive, and it can be difficult to predict which drugs will be effective.

Cognit Edge

High-Resolution Genomics: We aim to advance traditional views, aspiring to achieve significant insights into genetic interactions.

Phenotype Prediction: We are developing methods to accurately predict phenotypes from genotypes, enhancing our understanding of genetic expression and its implications.
 

Novel Biomarker Discovery: We are identifying novel biomarkers to facilitate early diagnosis and targeted treatments.

Episomal Gene Synthesis: We are advancing episomal gene synthesis techniques to improve gene therapy outcomes.

Ex-vivo and In-vivo Design: We are pioneering ex-vivo and in-vivo design strategies to enhance precision in genetic engineering and therapeutic applications.

Targeted Therapies: We are in the process of identifying and validating therapeutic targets at the Genomic level with high accuracy.

Decoding the Genome: By illuminating previously unknown genomic regions, we hope to broaden our understanding of tumorigenesis.

bottom of page